<DOC>
	<DOCNO>NCT02461199</DOCNO>
	<brief_summary>During prospective observational study , investigator collect information outcomes fecal microbiota transplantation patient blood disorder , perform eradicate gut colonization multidrug-resistant ( MDR ) bacteria . Patients blood disorder characterize poor diversity gut microbiome , affect repeat chemotherapy antimicrobial treatment . This make vulnerable colonization pathogenic bacteria carry gene responsible antibiotic resistance . In case gut mucosa injury severe immune suppression , colonize bacteria may cause severe systemic infection . As bacteria secrete stool , colonized patient become epidemiologic threat others . Fecal microbiota transplantation ( FMT ) show efficient treatment relapse refractory Clostridium difficile infection become standard treatment . In home institution , investigator use FMT case Clostridium difficile colitis , also case gut colonization multidrug-resistant ( MDR ) bacteria . This base assumption physiological gut flora may outcompete pathogenic bacteria similarly case Clostridium difficile lead loss colonization . The procedure perform patient colonize , qualify accord listed inclusion exclusion criterion .</brief_summary>
	<brief_title>Stool Transplantation Reduce Antibiotic Resistance Transmission</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>Age &gt; 18 Carrier status MDR bacteria stool : Klebsiella pneumoniae resistant carbapenems , Pseudomonas aeruginosa resistant carbapenems , Enterococcus faecalis VRE , Enterococcus faecium VRE , Enterobacter cloacae KPC+ MDR specie document least two stool culture Blood neutrophil count &gt; 500/uL day fecal microbiota transplantation Inability obtain informed consent lack consent Blood neutrophil count &lt; 500/uL day fecal microbiota transplantation expect decrease mention number within 2 consecutive day Intensive , myelosuppressive chemotherapy ( e.g . DHAP , ICE , ESHAP , HDCy , HDAraC , DA , condition allogeneic stem cell transplantation , BEACOPP ) plan within 2 consecutive day Patients 1 month hematopoietic stem cell transplantation Clinical sign mucositis Severe liver failure Patients undergoing intensive antimicrobial treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Fecal microbiota transplantation</keyword>
	<keyword>Gut colonization</keyword>
	<keyword>Multidrug-resistant bacteria</keyword>
	<keyword>Blood disorder</keyword>
	<keyword>Drug Resistance , Multiple</keyword>
	<keyword>Disease Eradication</keyword>
</DOC>